In a significant breakthrough for the treatment of liver disease, Novo Nordisk's Wegovy has received U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in ...

Wegovy is now positioned as the first and only GLP-1 treatment.

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the ...

A group of vaccine-skeptical doctors and mandate opponents is challenging the CDC’s childhood immunization schedule in ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

Two new studies raise questions about GLP-1 weight-loss drugs and vision risks. While findings show rare links to optic nerve damage and a slight rise in diabetic retinopathy, experts urge caution, ...